Cancer Patients & Survivors: Vaccine Views & Support for Immunization | ACS CAN Survey 2026

WASHINGTON, D.C. – A new survey from the American Cancer Society Cancer Action Network (ACS CAN) reveals strong support for vaccination among cancer patients and survivors, highlighting its importance for both personal protection and community health. The January 14-25, 2026, survey, conducted among 1,445 individuals diagnosed or treated for cancer within the last seven years, demonstrates that the vast majority believe vaccinations are crucial for those they encounter in healthcare settings and within their broader communities.

According to the findings, 88% of cancer patients and survivors consider it important for individuals they encounter in healthcare facilities to be up-to-date on vaccinations, and 83% feel the same way about members of their wider community. This underscores a significant understanding of the heightened vulnerability cancer patients often experience due to compromised immune systems, whether from the disease itself or from treatments like chemotherapy and radiation.

The Importance of Vaccination for Immunocompromised Individuals

Cancer and its treatment can significantly weaken the immune system, making individuals more susceptible to infections. Vaccines work by training the body to recognize and fight off specific pathogens without causing illness, offering a crucial layer of protection. The American Cancer Society notes that people with cancer may be able to receive some vaccines, and some may even be recommended, depending on the type of cancer, treatment status, immune system function, and overall health.

However, the survey also reveals a growing sense of confusion surrounding vaccination recommendations. Thirty-seven percent of respondents reported that recent news reports, debates, and changes to federal recommendations have made it difficult to determine whether they should receive certain vaccines. Sixteen percent have even skipped or delayed a vaccine they previously would have received as a result of this uncertainty. More than half (59%) found that recent recommendations for shared decision-making regarding specific vaccines added to the confusion.

Support for Vaccine Policies and Research

Despite the confusion, the survey demonstrates strong support for policies that promote vaccination. Nearly three-quarters (76%) of respondents oppose state limitations on vaccine access. An even larger majority – 86% – support school entry vaccination requirements, and over three-quarters (78%) oppose the elimination of such requirements, with 63% strongly opposing their removal. Support for including the HPV vaccine in school mandates is particularly strong, with a 3-to-1 ratio in favor.

“School immunization requirements play an important role in reducing risks to immunocompromised people, children, individuals with cancer and others facing serious illnesses,” stated Lisa Lacasse, president of ACS CAN. “The weakening or elimination of school requirements will reduce the number of children that are up to date on recommended vaccines, decrease community immunity putting vulnerable populations at risk, and contribute further to the current uptick in preventable illness.”

The survey also highlights a strong belief in the potential of vaccines within oncology itself. Eighty-four percent of cancer patients and survivors agree that the U.S. Should be investing in mRNA research, a technology that has shown promise in developing new cancer treatments and vaccines.

Navigating Vaccination During and After Cancer Treatment

The decision of whether or not to receive a vaccine during or after cancer treatment is complex and should be made in consultation with a healthcare provider. Different types of vaccines – live versus inactivated – carry different levels of risk for individuals with weakened immune systems. Live vaccines, which contain a weakened version of the virus or bacteria, may not be safe for those with significantly compromised immunity. Inactivated vaccines, which contain killed or inactive components, are generally considered safer.

The American Cancer Society emphasizes that vaccination decisions should be individualized, taking into account the specific type of cancer, treatment plan, immune status, and overall health of the patient. Flu and COVID-19 vaccines are often recommended for cancer patients, but timing and type may vary. Pneumococcal and RSV vaccines are also important considerations, depending on individual risk factors.

The ACS CAN survey underscores the importance of clear communication and accessible information regarding vaccination for cancer patients and survivors. Addressing the confusion surrounding current recommendations and ensuring continued investment in vaccine research are crucial steps in protecting this vulnerable population and promoting public health. The findings reinforce the idea that broad community immunization is not just a public health benefit, but a critical component of care for those living with and beyond cancer.